$1.42
-0.11%PepGen Inc., a clinical-stage biotechnology company, focuses on the development of oligonucleotide therapeutics for use in the treatment of severe neuromuscular and neurologic diseases. The company's lead product candidate is PGN-EDO51, an EDO peptide in Phase I clinical trials to treat individuals with Duchenne muscular dystrophy (DMD). It is also developing PGN-EDODM1, an EDO peptide-conjugated PMO for the treatment of myotonic dystrophy type 1, as well as EDO therapeutic candidates, such as PGN-EDO53, PGN-EDO45, and PGN-EDO44 for the treatment of DMD. The company was founded in 2018 and is headquartered in Cambridge, Massachusetts.
Warren Buffett's Owner Earnings DCF analysis for intrinsic value calculation
Base year metrics used for projections
Forecast period and terminal assumptions
Calculation flow from present value to intrinsic value per share
Operating Cash Flow - Maintenance CapEx = Owner Earnings
| Metric | Year 1 | Year 2 | Year 3 | Year 4 | Year 5 | Year 6 | Year 7 | Year 8 | Year 9 | Year 10 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -$82.6M | -$83.6M | -$84.5M | -$85.5M | -$86.5M | -$87.5M | -$88.6M | -$89.6M | -$90.6M | -$91.7M |
| Maintenance CapEx | -$53.4K | -$54.0K | -$54.7K | -$55.3K | -$56.0K | -$56.6K | -$57.3K | -$58.0K | -$58.6K | -$59.3K |
| Owner Earnings | -$82.6M | -$83.6M | -$84.6M | -$85.6M | -$86.6M | -$87.6M | -$88.6M | -$89.7M | -$90.7M | -$91.8M |
| Discount Factor | 0.926 | 0.857 | 0.794 | 0.735 | 0.681 | 0.630 | 0.583 | 0.540 | 0.500 | 0.463 |
| Present Value | -$76.5M | -$71.7M | -$67.2M | -$62.9M | -$58.9M | -$55.2M | -$51.7M | -$48.4M | -$45.4M | -$42.5M |
Continue your PEPG research with focused valuation guides.
Snapshot
Start with context, operating signals, and key market metrics.
Value Model
Stress test fair value across bear, base, and bull assumptions.
Statements
Validate revenue quality, margins, and balance sheet durability.
Earnings Call
Read management commentary and compare it with reported outcomes.
Dividends
Check payout sustainability and long-term distribution behavior.
Analyst Expectations
Review consensus spread and where estimate risk is concentrated.